Treatment of negative schizophrenic symptoms with alprazolam: A preliminary open-label study

John G. Csernansky*, Leon Lombrozo, George D. Gulevich, Leo E. Hollister

*Corresponding author for this work

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Eight schizophrenic patients received alprazolam in an open-label protocol. A partial reversal of negative symptoms was noted in six of the eight patients. Also, all eight experienced a decrease in anxiety. Alprazolam in doses of 5 to 7 mg/day yielded steady state plasma levels of 6 to 64 ng/ ml. As the drug was well tolerated at these doses and as negative symptoms of schizophrenia are difficult to treat, a double-blind, controlled trial of alprazolam is underway to test more rigorously these preliminary results.

Original languageEnglish (US)
Pages (from-to)349-352
Number of pages4
JournalJournal of clinical psychopharmacology
Volume4
Issue number6
StatePublished - Dec 1984

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Treatment of negative schizophrenic symptoms with alprazolam: A preliminary open-label study'. Together they form a unique fingerprint.

  • Cite this